26
|
Noborio R, Nomura Y, Nakamura M, Nishida E, Kiyohara T, Tanizaki H, Morita A. Efficacy of 308-nm excimer laser treatment for refractory vitiligo: a case series of treatment based on the minimal blistering dose. J Eur Acad Dermatol Venereol 2020; 35:e287-e289. [PMID: 33232541 DOI: 10.1111/jdv.17047] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
27
|
Nakamura M, Obayashi M, Yoshimitsu M, Kato H, Morita A. Comparative whole-exome sequencing of an ultra-late recurrent malignant melanoma. Br J Dermatol 2020; 184:762-763. [PMID: 33205417 DOI: 10.1111/bjd.19680] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2020] [Revised: 11/12/2020] [Accepted: 11/12/2020] [Indexed: 11/29/2022]
|
28
|
Le THH, Morita A, Tanaka T. Refractive index of nanoconfined water reveals its anomalous physical properties. NANOSCALE HORIZONS 2020; 5:1016-1024. [PMID: 32373853 DOI: 10.1039/d0nh00180e] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
Despite extensive studies on the distinctive properties of water confined in a nanospace, the underlying mechanism and significance of the lengthscale involved in the confinement effects are still subjects of controversy. The dielectric constant and the refractive index in particular are key parameters in modeling and understanding nanoconfined water, yet experimental evidence is lacking. We report the measurement of the refractive indices of water in 10-100 nm spaces by exploiting the confinement of water and localized surface plasmons in a physicochemically well-defined nanocavity. The results revealed significantly low values and the scaling behavior of the out-of-plane refractive index n⊥ of confined water. They are attributed to the polarization suppression at the interfaces and the long-range correlation in electronic polarization facilitated by the strengthened H-bonding network. Using the refractive index as a sensing probe, we also observed anomalous stability of water structures over a wide range of temperature. Our measurement results provide essential feedback information for benchmarking water models and molecular interactions under nanoconfinement. This study also opens up a new methodology of using plasmon resonance in characterizing nanoconfined molecules and chemical reactions, and thus gives us fundamental insight into confinement effects.
Collapse
|
29
|
Yamamoto T, Fukuda K, Morita A, Kimura T, Morishima H, Goto R, Zheng R, Terui T. Efficacy of guselkumab in a subpopulation with pustulotic arthro-osteitis through week 52: an exploratory analysis of a phase 3, randomized, double-blind, placebo-controlled study in Japanese patients with palmoplantar pustulosis. J Eur Acad Dermatol Venereol 2020; 34:2318-2329. [PMID: 32173916 PMCID: PMC7586986 DOI: 10.1111/jdv.16355] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2019] [Accepted: 02/18/2020] [Indexed: 12/11/2022]
Abstract
Background Previous studies of guselkumab have demonstrated clinical benefits in patients with plaque‐type psoriasis, generalized pustular psoriasis, erythrodermic psoriasis and palmoplantar pustulosis (PPP). Objective The aim of this exploratory analysis of a double‐blind, multicenter, placebo‐controlled, phase 3 study in Japanese patients with PPP was to evaluate the efficacy of guselkumab in the subset of patients with pustulotic arthro‐osteitis (PAO). Methods Patients were randomized to receive guselkumab 100 or 200 mg at weeks 0, 4, 12 and every 8 weeks, or placebo with cross‐over to guselkumab 100 or 200 mg at week 16 (placebo group). Efficacy endpoints were changes from baseline in magnetic resonance imaging (MRI) score, EuroQOL‐5 dimensions (EQ‐5D) index score, EQ‐5D pain/discomfort dimension score and C‐reactive protein (CRP, mg/L) level in all PAO patients through week 52. Data from both guselkumab groups were combined and presented as results for a single overall guselkumab group. Results Among 159 patients with PPP, 66 with PAO were randomized across treatment groups. For patients with MRI data for all regions assessed, the proportion of patients in the guselkumab group with PAO characterized as severe decreased from 23.8% (10/42) at baseline to 5.4% (2/42) at week 52. The mean (SD) change from baseline at week 52 in EQ‐5D index score was 0.20 (0.17) among PPP patients with PAO and 0.15 (0.17) among those without PAO in the guselkumab group. Among all PAO patients, the proportions with an EQ‐5D pain/discomfort dimension score of no or slight pain/discomfort in the guselkumab group increased from baseline to week 52 [33.3% (7/21) vs. 87.5% (35/40)]. The mean (SD) CRP levels decreased in all PAO patients in the guselkumab group at week 52 compared to baseline [−1.71 (8.16) mg/L]. Conclusion Guselkumab treatment showed beneficial outcomes for PAO signs and symptoms in Japanese patients with PPP.
Collapse
|
30
|
Lavrard I, Thaci D, Papp K, Gordon K, Morita A, Gooderham M, Foley P, Kisa R, Napoli A, Kundu S, Banerjee S. Impact de l’inhibiteur sélectif oral de la tyrosine kinase 2 (BMS-986165) sur la qualité de vie chez les patients atteints de psoriasis en plaques modéré à sévère dans un essai clinique de phase 2 évalué par l’index de dermatologie de qualité de vie (DLQI). Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.577] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
31
|
Lavrard I, Gordon K, Papp K, Gooderham M, Thaçi D, Foley P, Banerjee S, Kundu S, Kisa R, Napoli A, Morita A. Évaluation de l’influence des caractéristiques de la maladie à l’inclusion sur l’efficacité de l’inhibiteur sélectif de TYK2 oral (BMS-986165), chez les patients atteints de psoriasis en plaques modéré à sévère dans un essai clinique de phase 2. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.575] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
32
|
Kubo T, Nogami N, Bessho A, Morita A, Ikeo S, Yokoyama T, Ishihara M, Honda T, Fujimoto N, Murakami S, Kaira K, Harada T, Nakamura K, Iwasawa S, Shimokawa T, Kiura K, Yamashita N, Okamoto H. Phase II trial of carboplatin, nab-paclitaxel and bevacizumab for advanced non-squamous non-small cell lung cancer (CARNAVAL study; TORG1424/OLCSG1402). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz437.037] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
33
|
Morita A, Ikumi K. Can the dose and dosing interval of biologics be optimized? Br J Dermatol 2019; 182:264-266. [DOI: 10.1111/bjd.18457] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
|
34
|
Masuda H, Morita A. 559 Wavelength characteristics for UVA1 phototherapy with suppressed immediate pigment darkening. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.07.474] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
35
|
Nakamura M, Teramoto Y, Yasuda M, Wada H, Ozawa T, Umemori Y, Ogata D, Kobayashi T, Hata M, Morita A. 131 Loss of PD-L1 expression in metastatic Merkel cell carcinoma strongly correlates with a poor prognosis. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.03.207] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
36
|
Yamazaki S, Odanaka M, Shime H, Imai M, Hemmi H, Kaisho T, Ohkura N, Sakaguchi S, Morita A. 051 Dermal dendritic cells present neo-self antigens induced by ultraviolet B exposure to expand Foxp3+ regulatory T cells. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.03.127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
37
|
Nakamura M, Magara T, Kobayashi Y, Kato H, Watanabe S, Morita A. Heterogeneity of programmed death‐ligand expression in a case of Merkel cell carcinoma exhibiting complete regression after multiple metastases. Br J Dermatol 2019; 180:1228-1229. [DOI: 10.1111/bjd.17430] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
38
|
Kuroda Y, Fujino Y, Morita A, Tanioka Y, Suzuki V, Kawamura T, Ku Y, Saitoh Y. Successful 96-hour preservation of the canine pancreas. Transpl Int 2018. [DOI: 10.1111/tri.1992.5.s1.388] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
39
|
Kuroda Y, Fujino Y, Morita A, Tanioka Y, Suzuki Y, Kawamura T, Ku Y, Saitoh Y. The mechanism of action of the two-layer (Euro-Collins' solution/perfluorochemical) cold storage method in canine pancreas preservation. Transpl Int 2018. [DOI: 10.1111/tri.1992.5.s1.391] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
40
|
Nakamura M, Moosmann S, Krutmann J, Vogel C, Haarmann-Stemmann T, Morita A. 684 Aryl hydrocarbon receptor-dependent expression of aldo-keto reductase 1C3 in the pathogenesis of atopic dermatitis caused by air pollution. J Invest Dermatol 2018. [DOI: 10.1016/j.jid.2018.03.693] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
41
|
Ishihara M, Morita A, Hara M, Teramoto H, Shiobara K, Ogawa K, Shiota H, Suzuki Y, Kamei S. Clinical features of 6 cases of mollaret’s meningitis. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.3411] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
42
|
Torii K, Kubo R, Furuhashi T, Muramatsu S, Sagawa Y, Saito C, Yamazaki S, Morita A. 638 Photochemotherapy limits Treg plasticity and restores Treg function in psoriasis patients. J Invest Dermatol 2017. [DOI: 10.1016/j.jid.2017.07.314] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
43
|
Ikumi K, Nishida E, Morita A. 040 HLA-B46 associates with sacroiliitis susceptibility in patients with psoriatic arthritis. J Invest Dermatol 2017. [DOI: 10.1016/j.jid.2017.07.136] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
44
|
Nishida E, Ikumi K, Muramatsu S, Morita A. 065 The relationship between the balance of omega 3 and 6 fatty acids and the severity of psoriasis. J Invest Dermatol 2017. [DOI: 10.1016/j.jid.2017.07.161] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
45
|
Masuda H, Kimura M, Morita A. 730 Wavelength specific gene expression clustering identified by cap analysis of gene expression in normal human epidermal melanocytes. J Invest Dermatol 2017. [DOI: 10.1016/j.jid.2017.02.754] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
46
|
Torii K, Morita A. 762 Comparative transcriptome analysis in normal human keratinocytes irradiated with monochromatic UVB wavelength. J Invest Dermatol 2017. [DOI: 10.1016/j.jid.2017.02.786] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
47
|
Ikumi K, Nishida E, Morita A. 245 Sacroiliitis susceptibility of psoriatic arthritis in Asians is associated with HLA B46. J Invest Dermatol 2017. [DOI: 10.1016/j.jid.2017.02.260] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
48
|
Nishida E, Torii K, Kasuya S, Ikumi K, Morita A. 349 Quantifying of serum IL-17A and TNF-α to estimate the formation of psoriatic skin: PASI formula. J Invest Dermatol 2017. [DOI: 10.1016/j.jid.2017.02.366] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
49
|
Adachi K, Ansai S, Igarashi Y, Matano Y, Kitamura T, Morita A. P05.01 Anhidrosis in neurohypophyseal germinoma. Neuro Oncol 2017. [DOI: 10.1093/neuonc/nox036.168] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
50
|
van de Kerkhof P, Guenther L, Gottlieb AB, Sebastian M, Wu JJ, Foley P, Morita A, Goldblum O, Zhang L, Erickson J, Ball S, Rich P. Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3. J Eur Acad Dermatol Venereol 2016; 31:477-482. [PMID: 27910156 DOI: 10.1111/jdv.14033] [Citation(s) in RCA: 51] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2016] [Accepted: 10/11/2016] [Indexed: 11/27/2022]
Abstract
BACKGROUND Fingernail psoriasis is difficult to treat. OBJECTIVE The objective was to evaluate the effect of ixekizumab, a monoclonal antibody selectively targeting IL-17A, on fingernail psoriasis. METHODS This Phase 3, double-blind trial (UNCOVER-3) randomized patients to placebo, etanercept (50-mg twice weekly), or 80 mg ixekizumab as one injection every 4 (IXE Q4W) or 2 weeks (IXE Q2W) after a 160-mg starting dose. At Week 12, ixekizumab patients received open-label IXE Q4W through Week 60; placebo patients received a 160-mg starting ixekizumab dose and etanercept patients a 4-week placebo washout before starting IXE Q4W. Efficacy was assessed by mean per cent Nail Psoriasis Severity Index (NAPSI) improvement at Weeks 12 and 60. RESULTS Of 1346 patients in the UNCOVER-3 trial, this subgroup analysis included only patients with baseline fingernail psoriasis: 116 (60.1%) placebo, 236 (61.8%) etanercept, 228 (59.1%) IXE Q4W and 229 (59.5%) IXE Q2W. At Week 12, greater mean per cent NAPSI improvements were achieved in IXE Q4W (36.7%) and IXE Q2W (35.2%) vs. placebo (-34.3%, P < 0.001 each comparison) and etanercept (20.0%, P = 0.048 vs. Q4W, P = 0.072 vs. Q2W). At Week 60, mean per cent NAPSI improvement was >80% regardless of initial treatment. At Week 12 (nonresponder imputation), complete resolution (NAPSI = 0) was achieved in 19.7% (IXE Q4W), 17.5% (IXE Q2W), 4.3% (placebo, P < 0.001 each comparison) and 10.2% (etanercept, P < 0.05 each comparison) of patients. By Week 60, >50% of patients achieved complete resolution. CONCLUSIONS At Week 12, significant improvements in fingernail psoriasis were achieved with ixekizumab therapy. With IXE Q4W maintenance dosing, additional improvement was demonstrated through 60 weeks, and >50% of patients achieved complete resolution. Registered at clinicaltrials.gov: NCT01646177.
Collapse
|